LABORATORY RESEARCH Silencing of MicroRNA Families by Seed-Targeting Tiny LNAs Scientists developed a method that enables antagonism of miRNA function using seed-targeting 8-mer locked nucleic acid (LNA) oligonucleotides, termed tiny LNAs. [Nat Genet] Porphysome Nanovesicles Generated by Porphyrin Bilayers for Use as Multimodal Biophotonic Contrast Agents Researchers reported the development of porphysomes; nanovesicles formed from self-assembled porphyrin bilayers that generated large, tunable extinction coefficients, structure-dependent fluorescence self-quenching and unique photothermal and photoacoustic properties. [Nat Mater] Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors Findings demonstrated that Carbonic Anhydrase IX (CAIX) is vital for growth and metastasis of hypoxic breast tumors and is a specific, targetable biomarker for breast cancer metastasis. [Cancer Res] S6 Kinase 2 Promotes Breast Cancer Cell Survival Via Akt In the present study, investigators examined the effects of S6 kinase 2 on Akt activation and cell survival. [Cancer Res] Activation of Toll-Like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth Findings indicate that TLR5 activation by flagellin mediates innate immune response to elicit potent antitumor activity in breast cancer cells themselves, which may serve as a novel therapeutic target for human breast cancer therapy. [Cancer Res] Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression The aim of the study was to analyze the global lipid profiles of breast cancer, integrate the results to protein expression and validate the findings by functional experiments. [Cancer Res] β-Catenin Is Required for Ron Receptor-Induced Mammary Tumorigenesis Data suggest that β-catenin is a crucial downstream regulator of Ron receptor activation and is an important mediator of mammary tumorigenesis. [Oncogene] YB-1 Evokes Susceptibility to Cancer through Cytokinesis Failure, Mitotic Dysfunction and HER2 Amplification Scientists developed a model of pre-malignancy to characterize the role of Y-box binding protein-1 (YB-1) during breast cancer initiation and early progression. [Oncogene] HEXIM1 Is a Critical Determinant of the Response to Tamoxifen As hexamethylene bis-acetamide-inducible protein 1 (HEXIM1) can inhibit estrogen receptor (ER) activity, researchers examined whether it has a critical role in the inhibitory effects of tamoxifen on ER. [Oncogene] Evaluation of the XRCC1 Gene as a Phenotypic Modifier in BRCA1/2 Mutation Carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 Investigators evaluated the XRCC1 gene that participates in the base excision repair pathway, as phenotypic modifier of BRCA1 and BRCA2. [Br J Cancer] Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis Cancer-specific alterations in DNA methylation are hallmarks of human malignancies; however, the nature of the breast cancer epigenome and its effects on metastatic behavior remain obscure. To address this issue, researchers used genome-wide analysis to characterize the methylomes of breast cancers with diverse metastatic behavior. [Sci Transl Med] CLINICAL RESEARCH Digoxin Use and the Risk of Breast Cancer in Women Scientists hypothesized that digoxin use might increase breast cancer incidence and examined if use might be associated with risk of breast cancer, categorized by estrogen receptor status. [J Clin Oncol] Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age with Early Breast Cancer Taking tamoxifen for the recommended 5 years reduces the risk of recurrence or contralateral breast cancer 15 years after starting treatment. [J Clin Oncol] Multifactorial Approach to Predicting Resistance to Anthracyclines The neoadjuvant Trial of Principle study was specifically designed to evaluate the predictive value of topoisomerase II-α and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. [J Clin Oncol] Detection of HER2 Amplification in Circulating Free DNA in Patients with Breast Cancer Results demonstrate for the first time the existence of amplified human epidermal growth factor receptor 2 (HER2) in circulating free DNA in the follow-up of breast cancer patients who are otherwise disease free. This approach could potentially provide a marker in patients with HER2-positive breast cancer. [Br J Cancer] |